ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1059

Anti-mitochondrial Autoantibodies Are Associated with Cardiomyopathy, Dysphagia, and Features of More Severe Disease in Adult-onset Myositis

Sara Sabbagh1, Iago Pinal-Fernandez2, Maria Casal-Dominguez3, Jemima Albayda4, Julie Paik4, Frederick W. Miller2, Lisa G. Rider5, Andrew Mammen3 and Lisa Christopher-Stine4, 1Medical College of Wisconsin, Fox Point, WI, 2National Institutes of Health, Bethesda, MD, 3NIH, Bethesda, MD, 4Johns Hopkins University, Baltimore, MD, 5Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD

Meeting: ACR Convergence 2020

Keywords: Autoantibody(ies), Myositis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 8, 2020

Session Title: Muscle Biology, Myositis & Myopathies Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: We examined the prevalence of anti-mitochondrial autoantibodies (AMA) in adult- and juvenile-onset myositis longitudinal cohorts and investigated phenotypic differences between myositis patients with or without AMA.

Methods: We screened sera from myositis patients who were classified as adult- or juvenile-onset dermatomyositis (DM, JDM), polymyositis (PM, JPM), inclusion body myositis (IBM), or amyopathic DM, including 619 adults and 371 children, compared to healthy controls (64 adults and 92 children), for AMA by ELISA. Clinical characteristics were compared between myositis patients with and without AMA.

Results: AMA were present in 5% of adult myositis patients (16 DM, 10 PM, 4 IBM, 1 amyopathic DM), 1% of juvenile myositis patients (3 JDM, 1 JPM), and 1% of adult and juvenile healthy control subjects. In patients with adult-onset myositis, AMA were associated with persistent muscle weakness (90% vs 62%, p=0.005), DM-specific rashes (60% vs 41%, p=0.04), Raynaud’s phenomenon (43% vs 14%, p< 0.001), dysphagia (63% vs 36%, p=0.003), and cardiomyopathy (16% vs 5%, p=0.01). Adult myositis patients with AMA may have more severe or treatment refractory disease, as they more frequently received glucocorticoids (90% vs 67%, p=0.04), intravenous immunoglobulin (IVIG) (60% vs 29%, p=0.003), and overall received a higher total number of medications, including glucocorticoids, mycophenolate mofetil, methotrexate, IVIG, azathioprine, rituximab and cyclophosphamide, (2.8 vs 2.0, p=0.002) than those who were AMA negative. In juvenile myositis, children with AMA often had falling episodes (4/4) and dysphagia (3/4), but no other clinical features or medication usage were significantly associated with AMA.

Conclusion: AMA are present in 5% of adult myositis patients and associated with cardiomyopathy, dysphagia, persistent weakness, vasomotor instability, and additional therapy. The prevalence of AMA is not increased in patients with juvenile myositis compared to age-matched controls. These data suggest that the presence of AMA in adult myositis patients should prompt screening for cardiac and swallowing involvement.


Disclosure: S. Sabbagh, None; I. Pinal-Fernandez, None; M. Casal-Dominguez, None; J. Albayda, None; J. Paik, None; F. Miller, None; L. Rider, NIEHS, NIH, 2, Cure JM Foundation, 2, Bristol Myers Squibb, 2, Hope Pharmaceuticals, 2, Eli Lilly and Company, 9, MedImmune/AstraZeneca, 9; A. Mammen, None; L. Christopher-Stine, None.

To cite this abstract in AMA style:

Sabbagh S, Pinal-Fernandez I, Casal-Dominguez M, Albayda J, Paik J, Miller F, Rider L, Mammen A, Christopher-Stine L. Anti-mitochondrial Autoantibodies Are Associated with Cardiomyopathy, Dysphagia, and Features of More Severe Disease in Adult-onset Myositis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/anti-mitochondrial-autoantibodies-are-associated-with-cardiomyopathy-dysphagia-and-features-of-more-severe-disease-in-adult-onset-myositis/. Accessed January 18, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-mitochondrial-autoantibodies-are-associated-with-cardiomyopathy-dysphagia-and-features-of-more-severe-disease-in-adult-onset-myositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.